Incannex Healthcare Limited — FY2023 Form 20-F
Period and scope: This is an annual report for the fiscal year ended June 30, 2023, with comparisons to FY2022—not a report for 2022 Q4. The company is an Australian clinical-stage pharmaceutical developer; its audited consolidated statements are in Australian dollars (A$) and prepared under IFRS. It reported no product revenue in FY2023 or FY2022.
Financial performance and position
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | A$0 | A$0 |
| Other income | A$1.38 million | A$0.79 million |
| Total expenses | A$21.36 million | A$15.69 million |
| Net and comprehensive loss | A$19.98 million | A$14.90 million |
| Basic and diluted loss per share | 1.30 cents | 1.25 cents |
| Net cash used in operating activities | A$15.94 million | A$12.81 million |
| Cash and cash equivalents at year-end | A$33.36 million | A$37.50 million |
- Other income included A$1.01 million in refundable Australian R&D tax offsets and A$0.36 million in interest income. No income tax benefit was recognized; A$29.64 million of tax losses remained unrecognized as a deferred tax asset.
- Cash flows from investing activities were an outflow of A$0.48 million, primarily for property and equipment. Financing activities provided A$12.28 million, mainly from a A$13 million share placement; cash declined A$4.14 million overall.
- Year-end total assets were A$88.59 million, including A$52.72 million of acquired intangible assets; total liabilities were A$4.46 million, including A$0.79 million of lease liabilities. The filing reports no material conventional debt balance. Net assets were A$84.13 million.
- Current assets were A$34.69 million and current liabilities A$3.85 million. Management estimated existing cash would fund operations through October 2024, while cautioning that this estimate is forward-looking and uncertain.
- Margins are not meaningful because the company had no product revenue. No dividends were declared.
Material changes and business developments
- Net loss increased 34% year over year, principally reflecting greater clinical-development spending and higher salaries and employee benefits. R&D expense rose 74% to A$9.36 million. Share-based payment expense increased to A$3.19 million.
- Operating cash outflow increased 24% as clinical and R&D activities expanded. Financing cash inflow fell from A$41.18 million in FY2022, when substantial option exercises generated proceeds, to A$12.28 million in FY2023.
- The August 2022 APIRx acquisition was accounted for as an asset acquisition, not a business combination. Consideration included 218.2 million ordinary shares; acquired patents, trademarks and other IP were recorded at A$52.72 million. The filing describes APIRx as adding a broad cannabinoid-development portfolio.
- Development programs include IHL-42X for obstructive sleep apnea, IHL-216A for traumatic brain injury, IHL-675A for inflammatory conditions, and psilocybin-assisted psychotherapy for generalized anxiety disorder, alongside APIRx programs. The company remains pre-commercial.
Outlook, commentary and risks
- No formal financial guidance was provided. Management expects substantial losses and R&D spending to continue, does not expect significant product revenue for several years, and anticipates needing additional funding to complete development and pursue commercialization.
- For IHL-42X, a small Phase 2 proof-of-concept study (10 participants completing treatment periods) reported a 44.4% average AHI reduction across doses versus baseline; the low-dose result was strongest in certain analyses. These early findings are not proof of efficacy in larger trials. The FDA cleared the IND after year-end, in August 2023, allowing the planned Phase 2/3 study to proceed.
- For Psi-GAD, company analysis of interim data from the first 29 participants estimated a greater than 85% probability of a statistically significant benefit at the trial endpoint. The company states this was its own modeling, based on assumptions about the remaining participants, and was not verified by the independent Data Safety Monitoring Board. The board recommended no study-design change and reported no safety concerns.
- IHL-675A’s Phase 1 study in 36 healthy volunteers reported no serious adverse events or adverse events of concern. The planned rheumatoid-arthritis Phase 2 study was expected to recruit 128 patients; HREC approval and the expected Q4 2023 recruitment timing were reported after the fiscal year-end.
- IHL-216A’s GMP manufacturing was put on hold amid changed priorities and market conditions. Its reported supporting evidence is preclinical; the filing says some results had not been assessed for statistical significance.
- Key risks include clinical-trial failure or delay, regulatory and controlled-substance requirements, dependence on contract manufacturers and CROs, uncertain market acceptance and reimbursement, patent challenges, and the need for further financing. Equity financing may dilute holders; the company has no ready access to credit facilities.
- The company reported no material contingent liabilities, no material capital commitments, and no material legal proceedings. Management reported disclosure controls and internal control over financial reporting were effective as of June 30, 2023. The auditor issued an unqualified IFRS opinion; it did not attest to internal-control effectiveness because the company qualified as an emerging growth company.
- After year-end, the company announced a proposed redomiciliation to Delaware, subject to shareholder, optionholder, regulatory and court approvals. This was a proposed transaction, not a completed year-end event.
Important facts for investors to verify
- Confirm the reporting period: FY2023 ended June 30, 2023; the filing does not provide standalone 2022 Q4 results.
- Track actual cash burn, subsequent financing, and whether the stated cash runway through October 2024 remains achievable.
- Verify progress, recruitment, endpoints and results for the IHL-42X Phase 2/3 trial and Psi-GAD study; distinguish company interim estimates from final, independently reviewed results.
- Assess the assumptions and impairment sensitivity behind the A$52.72 million APIRx intangible-asset valuation, including its long-term revenue forecasts.
- Review dilution from the APIRx share consideration, FY2023 placement, advisor awards and outstanding options, as well as any future capital raising or redomiciliation terms.